<DOC>
	<DOCNO>NCT00956436</DOCNO>
	<brief_summary>This phase 1b , open-Label study sorafenib BIIB022 subject advance hepatocellular carcinoma .</brief_summary>
	<brief_title>Sorafenib With BIIB022 Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age ≥18 year Histologicallyconfirmed advance HCC least 1 target lesion measurable modified RECIST . ChildPugh score A5 A6 . ECOG Performance Status ≤2 . Known central nervous system brain metastasis . Prior antiIGF1R therapy . Prior systemic therapy advance HCC . Prior local therapy permit subject documented disease progression accord modified RECIST . Concurrent anticancer therapy . History myocardial infarction within 12 month prior Day 1 chronic heart failure . Acute hepatitis Fibrolamellar HCC Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Liver Cancer</keyword>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>HCC</keyword>
	<keyword>BIIB022</keyword>
	<keyword>Open-Label</keyword>
	<keyword>IGF-1R</keyword>
	<keyword>Nexavar</keyword>
</DOC>